RESULTS: We confirm that like decreased FOXA1 expression, decreased PTEN is common in bladder cancer. However, decreased PTEN expression is not associated with a specific morphologic characteristic or gene expression subtype. We show copy number alterations are likely a major factor determining PTEN expression, while FOXA1 expression is relatively independent of copy number. Combined inactivation of Foxa1 and Pten in mice results in the development of bladder cancer with squamous features. Additionally, exposure of these mice to a bladder-specific carcinogen results in rapid development of advanced disease with extensive squamous differentiation.
INTRODUCTION AND OBJECTIVES:
There is presently a major discrepancy between the critical role of PTEN knockout in the genesis of muscle-invasive bladder cancer (MIBC) in mice and the very low frequency (6-8%) of PTEN mutation or deletion in the human counterpart. We undertook this study to examine the alternative mechanism(s) of PTEN inactivation, and found hyper-phosphorylation of PTEN, which functionally disables PTEN, to be extremely prevalent in human MIBC. This has several major theranostic implications.
METHODS: The status of PTEN and its phosphorylation were first assessed in a panel of human bladder cancer (BC) cell lines, and then in a collection of fresh human BC specimens by Western blotting, and then in a cohort of archived low-grade non-invasive and high-grade invasive BC, both with matching adjacent normal urothelial controls, by immunohistochemical (IHC) staining. In the case of PTEN phosphorylation, phosphorylation site-specific antibodies were used. The effects of PTEN phosphorylation in functionally inactivating PTEN were established by transfecting PTEN-lacking BC cell lines (UMUC3 and J82) with wild-type PTEN or PTEN bearing phosphorylationincompatible mutations or deletion. Their effects on cell growth, migration, AKT phosphorylation, cell-cycle progression and apoptosis were assessed in vitro and in xenograft mouse models.
RESULTS: All but two BC cell lines (UMUC3 and J82) expressed PTEN and whenever PTEN was expressed, it was hyperphosphorylated at the C-terminus. By Western blotting of fresh human BC specimens, 10/12 (83%) of the low-grade non-muscle-invasive BC (NMIBC) and high-grade muscle-invasive MIBC contained PTEN, and in all the positive tumors PTEN was hyper-phosphorylated at the C-terminus. By IHC, phosphorylated PTEN was significantly higher in BC, particularly MIBC than matching normal urothelia. Functional studies showed that PTEN phosphorylation drove PTEN from the membrane into the cytoplasm where it was much less active, and that wild-type PTEN was much less effective than PTEN bearing phosphorylation-incompatible amino acids or C-terminal deletion in growth inhibition in vitro and in nude mice.
CONCLUSIONS: PTEN phosphorylation is a major mechanism of inactivation in human bladder cancer, and it should be used as biomarker, instead of PTEN itself, for diagnosing, subtyping and predicting the progression of bladder cancer.
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MP51-14 HYPERCHOLESTEROLEMIA PROMOTES THE PROGRESSION OF BLADDER CANCER IN SEVERAL MICE MODELS.
Lin Yang*, Jun Yan, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Hypercholesterolemia was reported to be associated with several cancers, such as prostate cancer, breast cancer and colorectal cancer. Urinary bladder cancer (UBC) is one of the most common urogenital malignancies. Whether hypercholesterolemia plays a role in UBC progression remains unclear. Our objective was to investigate the influence of hypercholesterolemia on UBC progression by several mice models.
METHODS: 1) Diet induced hypercholesterolemia model. Nude mice were fed with low fat no cholesterol diet (LFNC) or high fat high cholesterol diet (HFHC) w/o ezetimibe (EZ), which inhibited the absorption of cholesterol. T24 xenografts were injected once model established. Tumor growth, etc were measured. 2) BBN induced in situ bladder cancer model in wildtype mice and LDLR-/-mice. Tumor progression was analyzed. 3) MB49 allografts and tail vessel injected lung metastasis model. Allografts' growth and lung metastases were measured.
RESULTS: 1) Diet induced hypercholesterolemia promoted UBC progression (Figure 1) . 2) BBN induced UBC was promoted in LDLR-/-mice, a spontaneous hypercholesterolemia mouse model. UBC in situ progressed much faster in LDLR-/-mice ( Figure 2B ) with more lymph node and lung metastases ( Figure 2C and 2D ). Shorter survival curve was found in LDLR-/-mice ( Figure 2E ). 3) Enhanced progression, metastasis of MB49 injected were found in LDLR-/-mice compared to those in wildtype mice. MB49 allografts' growth was enhanced in LDLR-/-mice with lung metastases which were not detected in wildtype mice ( Figure 3A to 3C ). Tail vessel injection induced lung metastasis of MB49 showed that enhanced metastasis ability was detected in LDLR-/-mice ( Figure 3D to 3F).
CONCLUSIONS: Hypercholesterolemia could promote the progression of UBC, which was confirmed in several mice models.
